Navigation Links
OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February
Date:2/8/2017

SAN DIEGO, Feb. 8, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new clinical data on ImmunoPulse® IL-12, its lead program focused on oncology, at the upcoming 2017 American Association for Cancer Research & Society for Immunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology Symposium. In addition, Punit Dhillon, President & CEO, will present a corporate overview at two investment conferences in February, including: the 19th Annual BIO CEO & Investor Conference and Source Capital Group's 2017 Disruptive Growth & Healthcare Conference.

2017 ASCO-SITC Clinical Immuno-Oncology Symposium Dr. Alain Algazi, Associate Clinical Instructor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, will present an oral and poster presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium to be held on February 23-24, 2017, in Orlando, FL.

Details of the presentation are as follows:

Abstract Title: Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12) (Abstract ID #78) Session Title: Activating the Immune System-New Clinical Approaches Date and Time: February 23, 2017 at 11:30 a.m. – 1:00 p.m. (poster) & 3:30 p.m. – 5:00 p.m. EST (oral) Location: Hyatt Regency Orlando

Further details on this ASCO-SITC oral and poster presentation will be provided in upcoming Company communications. For more information about this symposium, please visit: http://immunosym.org/

The 19th Annual BIO CEO & Investor Conference Mr. Dhillon will present a corporate overview at The 19th Annual BIO CEO & Investor Conference on February 14 at 3:00 p.m. EST at The Waldorf Astoria in New York City.

To view to the live webcast, please access the following link at the time of the presentation: http://www.veracast.com/webcasts/bio/ceoinvestor2017/98226117037.cfm. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.

For more information about this conference, please visit: https://www.bio.org/events/bio-ceo-investor-conference

Source Capital Group's 2017 Disruptive Growth & Healthcare Conference Mr. Dhillon will present a corporate overview at Source Capital Group's 2017 Disruptive Growth & Healthcare Conference on February 15 at 3:00 p.m. EST at Convene in New York City.

For more information about this conference, please visit: www.DisruptNYC.com.

About OncoSec Medical Incorporated OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT: Punit Dhillon President & Chief Executive Officer OncoSec Medical Incorporated 855-662-6732 media@oncosec.com

Media: Laura Radocaj Dian Griesel Int'l. 212-825-3210

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-new-clinical-data-from-phase-2-combination-study-at-asco-sitc-clinical-immuno-oncology-symposium-and-corporate-updates-at-two-investment-conferences-in-february-300403831.html


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. OncoSec Announces First Quarter Financial Results for Fiscal Year 2017
2. OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016
3. OncoSec Appoints Sharron Gargosky, PhD, as Head of Clinical Development and Operations
4. OncoSec Opens New Headquarters and Research Facility in San Diego
5. OncoSec Announces First Quarter Results for Fiscal Year End 2016
6. OncoSec to Host First Quarter Financial Results Conference Call on December 8, 2015
7. OncoSec Medical Closes $7.5 Million Registered Direct Offering
8. OncoSec Announces $7.5 Million Registered Direct Offering
9. OncoSec Enrolls First Patient in Biomarker-Focused Pilot Study in Triple Negative Breast Cancer
10. OncoSec Issues Annual Letter To Shareholders
11. OncoSec Announces Fourth Quarter and YTD Results for Fiscal Year End 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global ... industries to improve patient outcomes and quality of life, will now be offering ... being attributed to new regulatory requirements for all new drug products, including the ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... it will be hosting a Webinar titled, “Pathology is going digital. Is your ... on digital pathology adoption best practices and how Proscia improves lab economics and ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
Breaking Biology Technology:
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
Breaking Biology News(10 mins):